Chongqing Pharscin Pharmaceutical Co., Ltd.
SZSE:002907.SZ
16.07 (CNY) • At close October 26, 2023
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 691.543 | 785.183 | 846.141 | 882.474 | 842.064 | 703.415 | 592.095 | 551.667 | 469.319 | 425.904 | 347.366 |
| Kosten van de omzet
| 311.348 | 319.292 | 399.925 | 458.306 | 307.085 | 230.77 | 195.362 | 196.575 | 178.11 | 154.388 | 128.589 |
| Brutowinst
| 380.194 | 465.891 | 446.216 | 424.168 | 534.979 | 472.645 | 396.734 | 355.092 | 291.209 | 271.516 | 218.777 |
| Brutowinstmarge
| 0.55 | 0.593 | 0.527 | 0.481 | 0.635 | 0.672 | 0.67 | 0.644 | 0.62 | 0.638 | 0.63 |
| Onderzoek- en ontwikkelingskosten
| 78.12 | 58.821 | 41.722 | 36.478 | 25.558 | 15.216 | 8.704 | 4.064 | 7.008 | 8.613 | 0 |
| Algemene en administratieve kosten
| 9.913 | 8.142 | 5.12 | 12.498 | 10.809 | 7.565 | 9.749 | 5.887 | 3.86 | 2.674 | 22.215 |
| Verkoop- en marketingkosten
| 210.74 | 245.935 | 258.591 | 225.146 | 290.789 | 279.342 | 239.258 | 218.08 | 179.039 | 181.352 | 159.784 |
| Verkoop-, algemene en administratieve kosten
| 220.653 | 254.076 | 263.711 | 237.643 | 301.598 | 286.907 | 249.006 | 223.967 | 182.899 | 184.026 | 181.999 |
| Overige kosten
| -3.026 | 34.002 | 34.166 | 11.524 | 6.706 | 2.436 | 1.327 | 21.537 | 17.288 | 13.084 | 9.997 |
| Bedrijfskosten
| 339.055 | 346.9 | 339.599 | 285.645 | 333.862 | 314.347 | 265.645 | 256.696 | 213.291 | 209.239 | 185.864 |
| Bedrijfsresultaat
| 45.823 | 108.83 | 103.312 | 137.438 | 198.262 | 158.471 | 131.052 | 93.629 | 73.479 | 56.704 | 27.588 |
| Bedrijfsresultaat ratio
| 0.066 | 0.139 | 0.122 | 0.156 | 0.235 | 0.225 | 0.221 | 0.17 | 0.157 | 0.133 | 0.079 |
| Totaal overige inkomsten en kosten netto
| -3.026 | -0.589 | 0.108 | -0.389 | -0.27 | 2.609 | 1.29 | 15.055 | 8.841 | 7.509 | 4.661 |
| Inkomen voor belasting
| 42.797 | 108.241 | 103.42 | 137.049 | 197.992 | 160.907 | 132.379 | 113.451 | 86.76 | 69.786 | 37.573 |
| Inkomen voor belasting ratio
| 0.062 | 0.138 | 0.122 | 0.155 | 0.235 | 0.229 | 0.224 | 0.206 | 0.185 | 0.164 | 0.108 |
| Belastingkosten
| 10.098 | 9.84 | 11.639 | 17.862 | 28.246 | 23.535 | 20.391 | 17.744 | 14.072 | 10.481 | 8.542 |
| Nettowinst
| 32.699 | 98.401 | 91.78 | 119.187 | 169.746 | 137.372 | 111.987 | 95.708 | 73.836 | 58.755 | 28.947 |
| Nettowinstmarge
| 0.047 | 0.125 | 0.108 | 0.135 | 0.202 | 0.195 | 0.189 | 0.173 | 0.157 | 0.138 | 0.083 |
| WPA (Winst Per Aandeel)
| 0.078 | 0.24 | 0.23 | 0.3 | 0.42 | 0.34 | 0.31 | 0.27 | 0.21 | 0.73 | 0.08 |
| Verwaterde WPA
| 0.078 | 0.24 | 0.23 | 0.3 | 0.42 | 0.34 | 0.31 | 0.27 | 0.21 | 0.73 | 0.08 |
| EBITDA
| 121.84 | 200.44 | 190.627 | 199.623 | 228.879 | 187.624 | 155.008 | 138.383 | 109.636 | 90.686 | 33.797 |
| EBITDA ratio
| 0.176 | 0.255 | 0.225 | 0.226 | 0.272 | 0.267 | 0.262 | 0.251 | 0.234 | 0.213 | 0.097 |